Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled TrialsMegan E. B. Clowse, Michelle Petri, Marilyn C. Pike et al.|Arthritis & Rheumatology|2016Cited by 237
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trialRonald van Vollenhoven, Eric F. Morand, Joseph F. Merola et al.|Poster presentations|2024Cited by 0